Table 1 Comparison of clinical features in the training and validation sets.

From: Delta radiomics analysis for prediction of intermediary- and high-risk factors for patients with locally advanced cervical cancer receiving neoadjuvant therapy

Clinical features

Training set

Test set

P

Tumor volume before treatment

31.20 ± 22.04

32.35 ± 29.74

0.809

Tumor volume after treatment

8.53 ± 8.59

8.26 ± 6.99

0.872

Tumor volume regression rate

0.70 ± 0.23

0.65 ± 0.25

0.334

Maximum tumor diameter before treatment

4.28 ± 1.19

3.99 ± 1.59

0.242

Maximum tumor diameter after treatment

1.80 ± 1.43

1.39 ± 1.21

0.145

WHO tumor regression rate

0.59 ± 0.31

0.63 ± 0.35

0.583

Recist v1.1 tumor regression rate

0.31 ± 0.35

0.47 ± 0.39

0.025

Pre-treatment HB

110.30 ± 18.14

118.48 ± 18.90

0.021

Pre-treatment SCC

8.66 ± 11.37

8.86 ± 12.71

0.443

after-treatment SCC

2.75 ± 4.23

2.73 ± 4.92

0.985

Age

51.86 ± 7.41

53.68 ± 7.56

0.224

Diameter

0.091

 < 4 cm

53(42.06%)

12(38.71%)

 

 ≥ 4 cm

73(57.94%)

19(61.29%)

 
Back to article page